P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY

• K. Weisel,
• A. Wadlund,
• G. Gungor,
• E. Dergarabetian,
• C. Pacheco,
• N. Masurkar,
• P. Rodriguez-Otero

Affiliations

K. Weisel

1 Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

A. Wadlund

2 Janssen, Janssen-Cilag AB, Kolonnvägen 45, Solna, Sweden

G. Gungor

3 Janssen, Kavacik, Keçeli Plaza, Ertürk Sk. No:13, 34810 Beykoz, Istanbul, Turkey

E. Dergarabetian

4 Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, United Kingdom

C. Pacheco

5 Cerner Enviza, France SAS, 198 avenue de France, Paris, France

N. Masurkar

5 Cerner Enviza, France SAS, 198 avenue de France, Paris, France

P. Rodriguez-Otero

6 Department of Hematology, Clinica Universidad de Navarra, Pamplona, Spain